Second‐Knee C‐Reactive Protein After 1‐Week Staged Bilateral Total Knee Arthroplasty
- 1Department of Orthopedic Surgery Wonju Severance Christian Hospital, Wonju College of Medicine, Yonsei University Wonju Republic of Korea
Abstract
Background: One‐week staged bilateral total knee arthroplasty (TKA) operates the second knee before the systemic response to the first has resolved. Whether a higher second‐knee C‐reactive protein (CRP) reflects expected carryover or a distinct second‐surgery response is unknown. Using each patient as their own control, we assessed how far this burden reflects carryover.
Methods: We retrospectively analyzed 216 patients who underwent 1‐week staged bilateral TKA between January 2020 and April 2026 (primary cohort: 210 staged within 9 days). Primary endpoints were the absolute CRP on Postoperative Days 2 and 5, with the Days 2–5 area under the curve as a complementary summary. Exploratory analyses examined the per‐surgery CRP increment from each operation's own floor, peak reproducibility, and operative‐magnitude adjustment. Paired comparisons used the Wilcoxon signed‐rank test.
Results: The second knee carried a higher absolute CRP burden than the first: median paired differences +1.44 mg/dL at Day 2, +0.70 at Day 5, and +3.74 mg · day/dL for the Days 2–5 area under the curve, all significant after Holm correction and robust to multiple imputation of missing values. From each operation's own floor, the second‐knee increment was smaller, but the Day‐5 proxy floor exceeded the directly measured pre‐second‐operation value by a median 2.58 mg/dL, underestimating that increment by the same amount. In the 14 patients with a measured floor and a complete increment pair, the increment difference was −0.55 mg/dL and did not reach significance (p = 0.15); the measured floor was itself of similar magnitude to the Day‐2 between‐knee difference. Peak CRP showed moderate within‐patient agreement (intraclass correlation 0.65).
Conclusions: In 1‐week staged bilateral TKA without tranexamic acid or routine corticosteroid, the second knee runs a higher absolute CRP course, consistent with substantial carryover from the first operation; the data cannot exclude an additional per‐surgery response or fix its share. Two periprosthetic joint infections occurred, one during the index admission and one at 48 months, and CRP was not tested against infection outcomes, so these data support no diagnostic threshold. A modestly higher second‐knee CRP may reflect the expected acute‐phase course but must not override clinical suspicion; prospective validation is needed.
Related
- Staged bilateral reverse sural artery flap reconstruction for severe frostbite of both feet in a patient with schizophrenia : A case report
- Bilateral Staghorn Calculi With Stent Encrustation in a Patient With an Ileal Conduit Requiring Staged Endourological Procedures: A Case Report.
- Staged Revision Reverse Total Shoulder Arthroplasty to Functional Hemiarthroplasty With Retained Humeral Implant: A Salvage Technique
- Chronic Bilateral Knee Pain Following Total Knee Arthroplasty Due to Titanium Allergy: A Case Report
- Static Bilateral Plantar Load Sharing One Month After Total Knee Arthroplasty for Varus Osteoarthritis: A Prospective Pedobarographic Equivalence Study.
BibTeX
@article{lee2026secondknee,
title = {{Second‐Knee C‐Reactive Protein After 1‐Week Staged Bilateral Total Knee Arthroplasty}},
author = {Jaemin Lee and Doo Sup Kim},
journal = {Orthopaedic Surgery},
year = {2026},
month = sep,
doi = {10.1111/os.70434},
url = {https://doi.org/10.1111/os.70434},
note = {CC BY-NC 4.0},
}
RIS
TY - JOUR
TI - Second‐Knee C‐Reactive Protein After 1‐Week Staged Bilateral Total Knee Arthroplasty
AU - Jaemin Lee
AU - Doo Sup Kim
PY - 2026
DA - 2026/09/16
JO - Orthopaedic Surgery
DO - 10.1111/os.70434
UR - https://doi.org/10.1111/os.70434
AB - Background: One‐week staged bilateral total knee arthroplasty (TKA) operates the second knee before the systemic response to the first has resolved. Whether a higher second‐knee C‐reactive protein (CRP) reflects expected carryover or a distinct second‐surgery response is unknown. Using each patient as their own control, we assessed how far this burden reflects carryover. Methods: We retrospectively analyzed 216 patients who underwent 1‐week staged bilateral TKA between January 2020 and April 2026 (primary cohort: 210 staged within 9 days). Primary endpoints were the absolute CRP on Postoperative Days 2 and 5, with the Days 2–5 area under the curve as a complementary summary. Exploratory analyses examined the per‐surgery CRP increment from each operation's own floor, peak reproducibility, and operative‐magnitude adjustment. Paired comparisons used the Wilcoxon signed‐rank test. Results: The second knee carried a higher absolute CRP burden than the first: median paired differences +1.44 mg/dL at Day 2, +0.70 at Day 5, and +3.74 mg · day/dL for the Days 2–5 area under the curve, all significant after Holm correction and robust to multiple imputation of missing values. From each operation's own floor, the second‐knee increment was smaller, but the Day‐5 proxy floor exceeded the directly measured pre‐second‐operation value by a median 2.58 mg/dL, underestimating that increment by the same amount. In the 14 patients with a measured floor and a complete increment pair, the increment difference was −0.55 mg/dL and did not reach significance (p = 0.15); the measured floor was itself of similar magnitude to the Day‐2 between‐knee difference. Peak CRP showed moderate within‐patient agreement (intraclass correlation 0.65). Conclusions: In 1‐week staged bilateral TKA without tranexamic acid or routine corticosteroid, the second knee runs a higher absolute CRP course, consistent with substantial carryover from the first operation; the data cannot exclude an additional per‐surgery response or fix its share. Two periprosthetic joint infections occurred, one during the index admission and one at 48 months, and CRP was not tested against infection outcomes, so these data support no diagnostic threshold. A modestly higher second‐knee CRP may reflect the expected acute‐phase course but must not override clinical suspicion; prospective validation is needed.
SN - 1757-7853
SN - 1757-7861
ER -